Cargando…
CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis
BACKGROUND: Pancreatic cancer is a lethal disease due to the high incidence of metastasis at the time of detection. CD133 expression in clinical pancreatic cancer correlates with poor prognosis and metastasis. However, the molecular mechanism of CD133-regulated metastasis remains unclear. In recent...
Autores principales: | Ding, Qiang, Miyazaki, Yumi, Tsukasa, Koichiro, Matsubara, Shyuichiro, Yoshimitsu, Makoto, Takao, Sonshin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931313/ https://www.ncbi.nlm.nih.gov/pubmed/24468059 http://dx.doi.org/10.1186/1476-4598-13-15 |
Ejemplares similares
-
mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions
por: Matsubara, Shyuichiro, et al.
Publicado: (2013) -
Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition
por: Miyazaki, Yumi, et al.
Publicado: (2016) -
CD133 Modulate HIF-1α Expression under Hypoxia in EMT Phenotype Pancreatic Cancer Stem-Like Cells
por: Maeda, Koki, et al.
Publicado: (2016) -
Expression of MUC17 Is Regulated by HIF1α-Mediated Hypoxic Responses and Requires a Methylation-Free Hypoxia Responsible Element in Pancreatic Cancer
por: Kitamoto, Sho, et al.
Publicado: (2012) -
CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer
por: Nomura, Alice, et al.
Publicado: (2015)